Sign In
Buy LLY
$1,083.23
+18.39 (+1.73%)
At Close: Jun 03, 2026
Why Eli Lilly Stock Slumped Today
07:55pm, Tuesday, 24'th Feb 2026
A rival just cut the price of a competing medication. This puts the list price of weight-loss drug Zepbound under pressure.
First Look: Gilead buys Arcellx; IBM sinks on AI; Bitcoin slides
07:37am, Tuesday, 24'th Feb 2026
Stock News Dimon warns on credit cycle: JPMorgan Chase (JPM) CEO Jamie Dimon cautioned that elevated asset prices and growing banking competition echo preâ200
First American Trust FSB Sells 863 Shares of Eli Lilly and Company $LLY
05:56am, Tuesday, 24'th Feb 2026
First American Trust FSB trimmed its holdings in shares of Eli Lilly and Company (NYSE: LLY) by 3.1% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exch
Compound Planning Inc. Has $6.65 Million Stake in Eli Lilly and Company $LLY
05:56am, Tuesday, 24'th Feb 2026
Compound Planning Inc. increased its position in Eli Lilly and Company (NYSE: LLY) by 6.9% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exch
Novo's stumbles burnish Lilly's widening lead in weight-loss drugs
12:09am, Tuesday, 24'th Feb 2026
With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it a helping hand. Then came the latest trial data for the Dani
Market Today: Tariffs, AI Jitters; LLY, MRK, WBD in Focus
05:39pm, Monday, 23'rd Feb 2026
Guru Stock PicksBernard Horn has made the following transactions:Reduce in XSWX: BARN by 39.89%Sold out in CGAdd in TSN by 18.45%New position in HKSE:01299Stock
Novo Nordisk Faces Setback as CagriSema Falls Short in Obesity Trial
02:14pm, Monday, 23'rd Feb 2026
Novo Nordisk (NVO) is experiencing a significant drop in stock value after its obesity drug candidate, CagriSema, failed to meet the primary endpoint in the RED
Novo Nordisk shares sink after weight loss drug fails to match Eli Lilly's in trial
12:12pm, Monday, 23'rd Feb 2026
Novo Nordisk stock fell Monday after it said its next-generation weight loss drug didn't meet its key goal of showing that it wasn't inferior to Eli Lilly's rival drug, in the latest blow to the Danis
Eli Lilly's Zepbound Gets FDA OK for Multi-Dose Pen
12:06pm, Monday, 23'rd Feb 2026
The company said the weight-loss drug will be available at the same self-pay price in either the single-dose vial format or the multi-dose pen that delivers four weekly injections from a single device
Novo Nordisk's Loss Is Eli Lilly's Gain
11:42am, Monday, 23'rd Feb 2026
Novo Nordisk's stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly's tirzepatide, marketed under the Zepbound and Mounjaro bra
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen
09:00am, Monday, 23'rd Feb 2026
Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some patien
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
09:00am, Monday, 23'rd Feb 2026
Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound® Zepbound patients can access all doses in either multi-dose KwikP
Novo Nordisk's next obesity drug falls short of Lilly rival, wiping billions off its market value
08:13am, Monday, 23'rd Feb 2026
Novo Nordisk (NYSE:NVO) attempt to reclaim the initiative in the obesity drug race has backfired, after its experimental next-generation treatment failed to prove it was as effective as a rival therap
Novo Nordisk Stock Plunges and Eli Lilly Jumps. It's All Down to This Weight-Loss Drug Trial.
06:32am, Monday, 23'rd Feb 2026
Novo shares slump after the Danish drugmaker's experimental obesity drug fails to beat Lilly's treatment in an 84-week trial.
Hillsdale Investment Management Inc. Lowers Holdings in Eli Lilly and Company $LLY
06:10am, Monday, 23'rd Feb 2026
Hillsdale Investment Management Inc. reduced its stake in Eli Lilly and Company (NYSE: LLY) by 16.0% during the third quarter, according to the company in its most recent Form 13F filing with the Secu
